Calliditas Therapeutics AB
STO:CALTX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
91.1
208.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CALTX stock under the Base Case scenario is 725.13 SEK. Compared to the current market price of 208 SEK, Calliditas Therapeutics AB is Undervalued by 71%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Calliditas Therapeutics AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CALTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Calliditas Therapeutics AB
Balance Sheet Decomposition
Calliditas Therapeutics AB
Current Assets | 1.2B |
Cash & Short-Term Investments | 797.3m |
Receivables | 222.6m |
Other Current Assets | 134.6m |
Non-Current Assets | 592.7m |
Long-Term Investments | 27.2m |
PP&E | 59.4m |
Intangibles | 471.7m |
Other Non-Current Assets | 34.5m |
Current Liabilities | 429.8m |
Accounts Payable | 151m |
Accrued Liabilities | 252.1m |
Other Current Liabilities | 26.6m |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 1B |
Other Non-Current Liabilities | 202.4m |
Earnings Waterfall
Calliditas Therapeutics AB
Revenue
|
1.6B
SEK
|
Cost of Revenue
|
-104.7m
SEK
|
Gross Profit
|
1.5B
SEK
|
Operating Expenses
|
-1.8B
SEK
|
Operating Income
|
-353.1m
SEK
|
Other Expenses
|
-127.2m
SEK
|
Net Income
|
-480.4m
SEK
|
Free Cash Flow Analysis
Calliditas Therapeutics AB
SEK | |
Free Cash Flow | SEK |
In Q2 2024, revenues hit SEK 559.8 million, up from SEK 269.4 million last year. TARPEYO sales surged 90% to $46.3 million. Despite costs related to the Asahi Kasei offer, adjusted operating profit was SEK 70.2 million. Full approval in Europe for Kinpeygo and a new patent for the cancer treatment, setanaxib, bolstered prospects. The company raised its 2024 revenue guidance to $165-$185 million, indicating strong market demand. Operational cash flow improved, with a minimal net cash decrease and a strong position of SEK 797.3 million at quarter-end.
What is Earnings Call?
CALTX Profitability Score
Profitability Due Diligence
Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
CALTX Solvency Score
Solvency Due Diligence
Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CALTX Price Targets Summary
Calliditas Therapeutics AB
Dividends
Current shareholder yield for CALTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CALTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Officers
The intrinsic value of one CALTX stock under the Base Case scenario is 725.13 SEK.
Compared to the current market price of 208 SEK, Calliditas Therapeutics AB is Undervalued by 71%.